117 search results for: Burden of Disease
The Benefits of Early Intervention in AD: More Than Skin Deep
Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
ADVENT at CEORL-HNS 2026
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.
Pediatric EoE Disease Burden Infographic
Learn about pediatric EoE disease burden and why early identification is key for pediatric patients with EoE
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.
Children and EoE: More Than Just Being a Picky Eater
Join Prof. Alexandra Papadopoulou as she reviews the multifaceted burden of children with EoE.
The Burden in Patients with CRSwNP and Coexisting Asthma
This video supports improved clinical awareness and encourages comprehensive care strategies for patients living with both CRSwNP and asthma.
Patient Burden in Eosinophilic Esophagitis
Drs. Kathryn Peterson and Ikuo Hirano and Profs. Ingrid Terreehorst and Arjan Bredenoord highlight the impact and burden of EoE on the quality of life of patients.
EoE Quest: Navigating the Patient Experience
Want to test your EoE knowledge while learning more about the patient journey? Try EoE Quest, an engaging and educational interactive experience.
